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Abstract
Background: Cancer can produce many different symptoms, some subtle and some not at all subtle. An increasingly
important issue in oncology is to evaluate quality of life (QoL) in cancer patients. The cancer-specific QoL is related to all
stages of this disease.
Objective: The aim of this study was to evaluate the QoL in cancer patients with solid tumors and at the different
chemotherapy cycles (CT).
Methods: This was a cross-sectional study. A total of  200 cancer patients were included. With some modification, the
European Organization for Research and Treatment of  Cancer QoL Questionnaire (EORTC QLQ-C30) was used to
measure QoL in the patients. The QoL in most subjects (66%) was fairly favorable.
Results: A significant relationship between the cancer type, pain intensity, and fatigue was found. However, none of  the
demographic variables (age, education, marital status, income) were significantly related to QoL. Nevertheless, significant
difference was found between the level of QoL in patients with < 2 CT cycles and/or with 3-5 cycles (p< 0.001).
Conclusion: Cancer is an important health issue influencing QoL. An appropriate treatment which may provide care to the
cancer patients is CT. A CT cycle may improve QoL in patients with solid tumors.
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Introduction
The term quality of  life (QoL) is used to evaluate
the general well-being of  individuals and societies.
According to the World Health Organization
(WHO), quality of life (QoL) defined as individual
perception of life, values, objectives, standards, and
interests in the framework of culture. A number of
illness-related factors exist that can affect QoL. The
amount of symptoms distressed experienced by an
individual has been related to QoL in a number of
people with cancer. QoL is increasingly being used
as a primary outcome measure in studies to evaluate
the effectiveness of treatment1-4. Patients generally
instead of measuring lipoprotein level, blood
pressure, and the electrocardiogram, make decisions
about their health care by means of QoL which
estimates the effects on outcomes important to
themselves5.
An increasingly important issue in oncology
is to evaluate QoL in cancer patients6. The cancer-
specific QoL is related to all stages of this disease7,8.
In fact, for all types of cancer patients general QoL
instruments can be used to assess the overall impact
of patients’ health status on their QoL; however hand
cancer-specific instruments assess the impact of a
specific cancer on QoL6. In some cancer diseases
(glioma for instance), QoL has become an important
endpoint for treatments comparison in randomized
controlled trials so that in these patients clinical studies
increasingly incorporate QoL as endpoint9.
Cancer can produce many different
symptoms, some subtle and some not at all subtle.
Some symptoms of cancer affecting QoL in patients
would be cancer type and stage, as some types of
cancer do not present any symptoms until they are
in advanced stages, time since diagnosis, patient
acceptance, intensity of the disease and the level of
psychological distress experienced by caregivers.
The main problems of  long-term cancer
survivors are in the areas of  social/emotional
support, health habits, spiritual/ philosophical view
of life, and body image concerns10-13. Many studies
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show good or adequate overall QoL in these patients.
However, among long-term survivors, psychosocial
issues and physical symptoms such as pain and
lymphedema, particularly the adverse effects of
systemic adjuvant therapy (chemotherapy) on QoL
still persist11-14.  The aim of this study was to evaluate
the QoL in cancer patients with solid tumors and at
the different chemotherapy cycles.
 
Methods
This study was a cross-sectional. A total of 200 cancer
patients were included in the present analysis. The
study was conducted in Tehran hospital. Before being
asked the subjects to participate and fill out QoL
questionnaire, a formal consent was obtained from
all of them.  If the following criteria met by the
patients15, then they were invited to participate:
(1) diagnosed with solid tumors,
(2) planning to receive chemotherapy,
(3) no history of other chronic disease such as diabetic
or heart disease, and
(4) aged 18 years or older.
With some modification, the European
Organization for Research and Treatment of  Cancer
QoL Questionnaire (EORTC QLQ-C30) was used
to measure QoL in the patients. The test consisted
of 56 questions and had arranged into 5 domains
(Table 1): (a) physical, role, cognitive, emotional, and
social functioning demographic data as well as
cancer/treatment information (b) patient’s general
conditions (c) patient’s physical activities (d) social
status and occupational function and (e) sleep pattern.
With the aid of a nurse and/or a medical student,
the questionnaires were filled out during interview.
Each question had an equal value and the QoL was
quantified as the sum of  the scores for all domains.
The scores were classified into three categories,
namely favorable, fairly favorable, and favorable. The
higher scores on this scale represent a better QoL.
The chi square test was used to find the correlation
of the clinical variables and QoL scores using the
SPSS software (version 14). The level of significance
was set at p < 0.05 for all tests.
 
Results
The quality of life was lower in the patients with
pain compared to those had no pain (Table 1). In
addition, statistical analyses indicated that there was
a significant relationship between the pain intensity
with reducing or losing body performance and QoL
(P <0.05). The majority of patients (54.5%) were
male, aged 18-75 years, with a mean age of 46.2
(650%), unmarried (44%), primary school graduates
(65%), and had not sufficient income (79.5%). The
relationship between cancer type and QoL is
depicted in Table 2.
Table 1: Frequency of  the pain intensity with QoL in cancer patients undergoing CT (N=200)
                                            Quality of life
Favourable      Fairly              Non Pain intensity
Sum                                 favorable       favorable
82 (41%) 16 (8%) 43 (21.5%) 23 (11.5%) Weak
62 (31%) 10 (5%) 44 (22%)           8 (4%)                    Mild
31 (15.5%)             2 (1%)               23 (11%)           7 (3.5%)    Intense
25 (12.5%) 6 (3%) 17 (8.5%)   2 (1%)  Intolerable
200 (100%) 34 (17%)           126 (63%)        40 (20%)  Total
Table 2: Frequency of  type of  cancer with QoL in cancer patients undergoing CT (N=200)
Quality of life
Sum Favorable Fairly favorable Non-favorable Type of cancer
43 (21.5%) 15 (7.5%) 27 (13.5%) 1 (5%) Breast
72 (36%) 11 (5.5%) 53 (26.5%) 8 (4%) GI system
18 (9%) 4 (2%) 8 (4%) 6 (3%) Respiratory
17 (8.5%) 4 (2%) 9 (4.5%) 4 (2%) Reproductive
17 (8.5%) 5 (2.5%) 5 (2.5%) 4 (3.5%) Bone
33 (16.5%) 6 (3%) 20 (10%) 7 (3.5%) Others
200 (100%) 46 (23%) 132 (66%) 22 (11%) Total
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GI (gastrointestinal) cancer at the stage III was the
most common cancer, accounting for 35-40% of
all the patients. Most of  the patients (85%) were
aware of their disease. Findings about QoL in the
rest of four domains depicts that the most common
problems in regard to this category were: fear about
future (29%), thinking about the disease and its
consequences (26.5%), impatient (24%), and
depression (17.5%). The QoL was fairly favorable
in majority (66%) of  the patients. There was no
correlation between the QoL and variables such as
age, sex, marital status, duration of disease, economic
conditions, and occupational function. Furthermore,
no correlation was found between QoL and the
patients’ educational level (literate or illiterate).
Table 3 shows relationship between fatigue
and QoL in cancer patients undergoing
chemotherapy. Patients with low fatigue had better
QoL than the others and in fact chi square test
showed a significant relationship between the fatigue
and QoL in cancer patients undergoing
chemotherapy.
Table 3: Frequency of  the fatigue with QoL in cancer patients undergoing CT (N=200)
Quality of life
Sum   Favorable              Fairly favorable   Non-favorable    Fatigue
39 (19.5%) 21 (10.5%) 18 (9%)               -               Weak
139 (69.5%) 24 (12%) 99 (49.5%)                16 (8%)                  Mild
22 (11%)                1 (0.5%)             15 (7.5%)                    6 (3%)                  Intense
200 (100%) 46 (23%) 132 (66%)        22 (11%)               Total
The relationship between QoL and the number of
CT cycles shows that majority (66%) of the patients
had fairly favorable QoL. A strong correlation was
found between QoL and number of  CT cycles.
Nevertheless, significant difference was found
between the level of QoL in patients with < 2 CT
cycles and/or with 3-5 cycles (p< 0.001). This was
the case also for the level of QoL in patients with e”
6 cycles (p< 0.001).
Discussion
An important issue in cancer care and research is
QoL. The QoL refers to “global well-being,”
including physical, emotional, mental, social, and
behavioral components. In the last few years, a
number of  informative and valid QoL tools have
become available to measure health-related QoL6.
The most widely applicable instrument to measure
the QoL in cancer patients is the EORTC QLQ-
C30.  Using this method, the current study assessed
the QoL in cancer patients undergoing CT. Several
studies support our findings on the influence of CT
on good or adequate QoL among the cancer patients
undergoing CT1,2. For instance Nematollahi showed
in patients suffering from lymphatic tumors that there
was a positive correlation between CT and QoL1.
Likewise, the QoL of African American women
with breast cancer was found to be relatively high;
cancer recurrence and metastasis to the lymphatic
glands had significant effect on the QoL17. It has
also been shown that CT had a measurable adverse
effect on QoL in women with node-positive
operable breast cancer18. The results of our study
indicate that CT may improve the QoL in cancer
patients.
Nowadays QoL has been introduced as an
endpoint for treatment comparisons in many cancer
types, particularly in advanced stages19. QoL also, as
an early indicator of disease progression could help
the physician in daily practice to closely monitor the
patients20. QoL may be considered to be the effect
of an illness and its treatment as perceived by
patients3 and is modified by factors such as
impairments, functional stress, perceptions and social
opportunities4.
As reducing mortality and ensuring optimal
health-related QoL are perhaps the main objectives
of medical care10, this study shows that improvement
of QoL in cancer patient can be carried out by means
of  CT. In fact, improving QoL is as important as
the survival benefit that a pharmacological treatment
may provide. However, this is not always the case.
For example, Nemati et al21 reported that the level
of QoL in the patients with leukemia was 87.5%
lower than that in the control group. The differences
might be due to different patients’ population
(sample size or patient age), or cancer types. The
current study selected patients (aged > 18 years) with
various solid tumors while Nemati et al21 sampled
40 adolescence patients (aged < 18 years) with
leukemia.
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In this study, the majority of  the patients
(68%) who had completed 3 or more cycles of CT
reported a fairly favorable or favorable level of
QoL. This may show that QoL is directly related to
cancer treatment procedure, i.e. CT.  Likewise,
except for a small group (13.3%) of the patients
that their sleep pattern was not favorable, the others
had good QoL. This implies that CT can lead to the
better sleep pattern in cancer patients. Our results
are consistent with other studies. For instance Chen
et al15  found that QoL in lung cancer patients during
the fourth cycles of CT improved slightly over the
baseline values; the patients perceived more sleep
disturbances during the early cycles of  CT. Similar
results have been found in patients suffering from
advanced cancer by Mystakidou22 and from breast
cancer by Fortner21.
The findings of the present study show that
there is no correlation between QoL and age, gender,
social status, marriage, and job. Similar results have
reported by Nematollahi16, Vedat et al.24, and
Rustøen25 studies. Further, there were no correlation
between extent of the disease and QoL. In contrast,
Rustøen25 and Holzner26 in two separate studies
found that the extent to which QoL of cancer
patients depends on the time elapsed since initial
treatment; with an increase in the extent of the disease,
a decrease in the QoL was observed. The difference
might be due to the duration of disease; the extent
of the disease in 87% of the patients of the current
study was less than two years whilst it was more
than 2 years in Rustøen25 and Holzner26 studies.
Conclusion
Cancer is an important health issue influencing QoL.
An appropriate treatment which may provide care
to the cancer patients is CT. The obtained results
here indicate a strong correlation between QoL and
number of  CT cycles in cancer patients. Since CT is
socially stigmatized in some countries e.g. Iran,
encouraging patients to complete a CT course might
play an important role in the treatment outcome and
the QoL in cancer patients.
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